ArticleMolecular therapy. Oncology2026
Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effects.
Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Integrating network toxicology with multi-omics approaches to elucidate molecular targets and pathway mechanisms in BPA-induced hepatocellular carcinoma.Molecular diversity · 2026Article
- Subcellular targeting of survivin peptides: A multi-axis approach to cancer therapy.Molecular therapy. Oncology · 2026Article
- Next-Generation Anticancer Peptides: Engineering, Nanotheranostics and Clinical Translation.Nanotheranostics · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Survivin, a homodimeric protein overexpressed in virtually all cancers, is largely absent in non-proliferating adult tissues. It is a multifunctional regulator of cellular homeostasis that plays critical roles in proliferation, apoptosis, and immune regulation, which are central to cancer development and progression. Using a peptide array composed of sequences from SMAC/Diablo-interacting proteins, we identified a SMAC-binding sequence within survivin. Here, we report the characterization of a 24-amino-acid peptide spanning key survivin domains: the homodimer interface, microtubule, nuclear import, and chromosomal passenger complex binding sites. The peptide binds survivin and interferes with its dimerization, disrupting interactions with itself and partner proteins such as tubulin. When engineered as stabilized cell-penetrating peptides targeted to the cytosol, mitochondria, or nucleus, they effectively inhibited proliferation, disrupted the completion of mitosis, and induced apoptosis. In lung tumor models, the peptides reduced tumor cell proliferation and growth, while activating anti-tumor immune responses. They increased CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.